These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 34414935)

  • 1. Prognostic significance of excision repair cross complementation group 1 rs2298881 in patients with gastric cancer receiving platinum-based chemotherapy: A PRISMA-compliant meta-analysis.
    Lv Y; Xu M; Sun Y; Liu Y; Zhao L; Liu X; Li Z; Shi G; Jia J; Bi L; Ma N; Zhang X; Qi C
    Medicine (Baltimore); 2021 Aug; 100(33):e26850. PubMed ID: 34414935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of ERCC1 and ERCC4 polymorphisms on response to prognosis in gastric cancer treated with FOLFOX-based chemotherapy.
    Lu ZM; Luo TH; Nie MM; Fang GE; Ma LY; Xue XC; Wei G; Ke CW; Bi JW
    Tumour Biol; 2014 Apr; 35(4):2941-8. PubMed ID: 24318989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic value of ERCC1 expression in gastric cancer patients treated with platinum-based chemotherapy: a meta-analysis.
    Wei KK; Jiang L; Wei YY; Wang YF; Qian XK; Dai Q; Guan QL
    Tumour Biol; 2014 Sep; 35(9):8721-31. PubMed ID: 24870596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of ERCC1 and ERCC2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy.
    Mo J; Luo M; Cui J; Zhou S
    Int J Clin Exp Pathol; 2015; 8(11):15065-71. PubMed ID: 26823845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis.
    Yin M; Yan J; Martinez-Balibrea E; Graziano F; Lenz HJ; Kim HJ; Robert J; Im SA; Wang WS; Etienne-Grimaldi MC; Wei Q
    Clin Cancer Res; 2011 Mar; 17(6):1632-40. PubMed ID: 21278243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
    Xu TP; Shen H; Liu LX; Shu YQ
    Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of excision repair cross-complementation group 1 expression for platinum-based chemotherapy and survival in gastric cancer: a meta-analysis.
    Yao A; Wang Y; Peng X; Ye R; Wang Q; Qi Y; Zhou F
    J Cancer Res Clin Oncol; 2014 Dec; 140(12):2107-17. PubMed ID: 24994039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic polymorphisms in nucleotide excision repair pathway influences response to chemotherapy and overall survival in osteosarcoma.
    Sun Y; Wu Y; Li W; Kong Z; Zou X
    Int J Clin Exp Pathol; 2015; 8(7):7905-12. PubMed ID: 26339355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of ERCC1 polymorphisms on the response to platinum-based chemotherapy: A systematic review and meta-analysis based on Asian population.
    Wu X; Lu W; Jiang C; Zhang D; Zhang W; Cui Y; Zhuo Z; Mei H; Wang Y; Zhang M; Chen S
    PLoS One; 2023; 18(5):e0284825. PubMed ID: 37141338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic polymorphisms of DNA repair pathways influence the response to chemotherapy and overall survival of gastric cancer.
    Zhou J; Liu ZY; Li CB; Gao S; Ding LH; Wu XL; Wang ZY
    Tumour Biol; 2015 Apr; 36(4):3017-23. PubMed ID: 25542228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Excision repair cross-complementation group 1 codon 118 polymorphism, micro ribonucleic acid and protein expression, clinical outcome of the advanced gastric cancer response to first-line FOLFOX-4 in Qinghai-Tibetan plateau population.
    Qi YJ; Cui S; Yang YZ; Han JQ; Cai BJ; Sheng CF; Ma Y; Wuren T; Ge RL
    J Cancer Res Ther; 2013; 9(3):410-5. PubMed ID: 24125975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic value of excision repair cross-complementation group 1 (ERCC1) in patients with small cell lung cancer (SCLC) receiving platinum-based chemotherapy: evidence from meta-analysis.
    Yang Y; Luo X; Yang N; Feng R; Xian L
    PLoS One; 2014; 9(11):e111651. PubMed ID: 25375151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic variability of DNA repair mechanisms influences chemotherapy outcome of gastric cancer.
    Yu H; Wu X; Zhang Y; Jin Z; Li G; Zhao H
    Int J Clin Exp Pathol; 2015; 8(4):4106-12. PubMed ID: 26097599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic variability of ERCC1 genes in NER pathway influences the treatment outcome of gastric cancer.
    Bai Y; Wang L; Li G; Fang X; Li Y; Yang S
    Int J Clin Exp Pathol; 2015; 8(10):13367-73. PubMed ID: 26722542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ERCC1 C118T polymorphism predicts clinical outcomes of colorectal cancer patients receiving oxaliplatin-based chemotherapy: a meta-analysis based on 22 studies.
    Qian YY; Liu XY; Wu Q; Song X; Chen XF; Liu YQ; Pei D; Shen LZ; Shu YQ
    Asian Pac J Cancer Prev; 2014; 15(19):8383-90. PubMed ID: 25339033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional genetic variants of XRCC4 and ERCC1 predict survival of gastric cancer patients treated with chemotherapy by regulating the gene expression.
    Cheng L; Qiu L; Wang M; Zhang R; Sun M; Zhu X; Wang Y; Wei Q
    Mol Carcinog; 2017 Dec; 56(12):2706-2717. PubMed ID: 28796378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between the ERCC1 polymorphism and platinum-based chemotherapy effectiveness in ovarian cancer: a meta-analysis.
    Tang N; Lyu D; Zhang Y; Liu H
    BMC Womens Health; 2017 Jun; 17(1):43. PubMed ID: 28623887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic review.
    Wang Z; Chen JQ; Liu JL; Qin XG; Huang Y
    BMC Gastroenterol; 2012 Sep; 12():137. PubMed ID: 23020798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer.
    Huang ZH; Hua D; Du X; Li LH; Mao Y; Liu ZH; Song MX; Zhou XK
    World J Gastroenterol; 2008 Nov; 14(41):6401-7. PubMed ID: 19009659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].
    Qi BL; Li Y; Wang N; Zhou RM; Hu P; Kang S
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):847-52. PubMed ID: 24444563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.